Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM2 | P50570 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | LATS1 | O95835 | 1/20 | 0.40 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8521658 | 0.98 | SMN1; SMN2 (0.52) | DNM2SMN1; SMN2CYP2D6TLR8CYP1A2 | |
| SCHEMBL30593302 | 0.95 | TLR8 (0.56) | DNM2SMN1; SMN2CYP2D6TLR8CYP1A2 | |
| SCHEMBL2638413 | 0.95 | TLR8 (0.56) | DNM2SMN1; SMN2CYP2D6TLR8CYP1A2 | |
| SCHEMBL15923123 | 0.89 | SMN1; SMN2 (0.46) | DNM2SMN1; SMN2CYP2D6TLR8CYP1A2 | |
| SCHEMBL30195099 | 0.87 | SMN1; SMN2 (0.54) | DNM2SMN1; SMN2CYP2D6TLR8CYP1A2 | |
| SCHEMBL5554310 | 0.87 | SMN1; SMN2 (0.54) | DNM2SMN1; SMN2CYP2D6TLR8CYP1A2 | |
| SCHEMBL235705 | 0.82 | NUDT1 (0.50) | SMN1; SMN2CYP2D6TLR8CYP1A2CYP3A4 | |
| SCHEMBL210080 | 0.81 | NUDT1 (0.49) | DNM2SMN1; SMN2CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL18906038 | 0.80 | NUDT1 (0.56) | SMN1; SMN2CYP2D6CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL30775333 | 0.80 | NUDT1 (0.56) | SMN1; SMN2CYP2D6CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0954315-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | Sugen, Inc. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1998010767-A9 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | — | 1998-07-02 | — | — | WO | claimed |
| WO-1998010767-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | SUGEN, INC. (US) | 1998-03-19 | — | — | WO | claimed |
| CN-114644596-B | Fluoropyrimidine aromatic amine compound and application thereof | 青岛科技大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-114644596-A | Fluorine-containing pyrimidine arylamine compound and application thereof | 青岛科技大学 | 2022-06-21 | — | — | CN | disclosed |
| CN-114605335-A | Pyrimidine thioether amine ester pesticide | 青岛科技大学 | 2022-06-10 | — | — | CN | disclosed |
| EP-3590928-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-06-09 | — | — | EP | disclosed |
| US-10966985-B2 | Macrocyclic compounds as ROS1 kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10688100-B2 | Macrocylic compounds as ROS1 kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-06-23 | — | — | US | disclosed |
| CN-110769820-A | Macrocyclic compounds as ROS1 kinase inhibitors | 阿雷生物药品公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20190151322-A1 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-05-23 | — | — | US | disclosed |
| EP-1418916-A1 | 2-AMINO-4-HETEROARYLAMINOPYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
| US-20030125346-A1 | Amino-substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2003018022-A1 | 2-AMINO-4-HETEROARYLAMINOPYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
| EP-0954315-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | Sugen, Inc. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1998010767-A9 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | — | 1998-07-02 | — | — | WO | disclosed |
| WO-1998010767-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | SUGEN, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| US-4285946-A | ANOREXIGENIC AGENTS; TREATING DISTURBANCES OF THE METABOLISM OF LIPIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | DNM2 3952/4885SMN1; SMN2 1697/4885CYP2D6 23/4885 |
| US-20030125346-A1 | Amino-substituted pyrimidinyl derivatives and methods of use | TYMP, DPYD, TPMT | DNM2 3483/4885SMN1; SMN2 2334/4885CYP2D6 50/4885 |
| US-10966985-B2 | Macrocyclic compounds as ROS1 kinase inhibitors | ROS1, MAP3K1, MAP3K19 | DNM2 1271/4885SMN1; SMN2 3781/4885CYP2D6 3539/4885 |
| US-10688100-B2 | Macrocylic compounds as ROS1 kinase inhibitors | ROS1, MAP3K1, MAP3K11 | DNM2 1652/4885SMN1; SMN2 4051/4885CYP2D6 3340/4885 |
| US-20190151322-A1 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | ROS1, MAP3K1, MAP3K19 | DNM2 1271/4885SMN1; SMN2 3781/4885CYP2D6 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.